The DEA begins reviewing its proposal to move cannabis to Schedule III, even as reform advocates criticize their exclusion ...

Both a DEA lawyer and an FDA official spoke to justify rescheduling—arguments that were condemned by a prominent ...

Three Republican attorneys general are asking a federal appeals court to block the Trump administration's push to reschedule ...

The DEA's cannabis rescheduling hearing runs through a July 15 deadline, putting cannabis stocks and the MSOS ETF in focus.

Cannabis investors have seen rescheduling euphoria ignite and incinerate capital at least four times since 2018, and a fresh ...

The cannabis industry won't have a direct voice in potentially historic hearings next week. And a final outcome is far from certain.

The Drug Enforcement Administration is scheduled to hold a historic hearing beginning Monday, June 29, 2026, which could ...

The MSOS cannabis ETF hit a 2026 high ahead of the DEA's July 15 rescheduling deadline, as Trulieve, Curaleaf and Canopy Growth reshape the sector.

This may be an encouraging sign for those advocating for the rescheduling of cannabis in a way that will survive the inevitable legal challenge(s) that would follow rescheduling.” By Brett Schuman and ...

The Drug Enforcement Administration is considering a proposal to move marijuana from Schedule I to Schedule III of the ...

There was no discussion of the lasting harms of marijuana criminalization itself—the arrests, convictions, incarceration and collateral consequences that continue to affect individuals, families and ...

Tilray's stock initially surged as much as 19% Thursday on the reclassification news, but then sold off to close down 12% Cannabis stocks initially flew high on the rescheduling, but ended Thursday ...